Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients

Lino Del Pup

Research output: Contribution to journalArticlepeer-review


Cancer patients suffer from vaginal dryness and dyspareunia earlier and longer than the general population, with more severe and distressing symptoms. Life-style advices are the first step and vaginal lubricants can be tried, but they can't completely relieve atrophic symptoms. The most effective therapy is use of vaginal estrogens, but compliance and management are particularly difficult in estrogen sensitive cancer patients because of their systemic absorption. Compliance can be improved if they are begun at a very low dose and gradually increased until the lowest effective dose is reached. Promestriene only possesses an intramucosal effect, it can be used at very low doses in cancer patients suffering from urogenital symptoms.

Original languageEnglish
Pages (from-to)740-745
Number of pages6
JournalGynecological Endocrinology
Issue number9
Publication statusPublished - Sep 2012


  • Dyspareunia
  • Female cancer patients
  • Promestriene
  • Vaginal dryness
  • Vaginal estrogens

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Obstetrics and Gynaecology


Dive into the research topics of 'Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients'. Together they form a unique fingerprint.

Cite this